Study of two drugs for follicular lymphoma that came back
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma (grade 1, 2, or 3a) that has come back or not responded to at least one prior treatment.
- You have measurable disease on a scan (for example, a lymph node at least 1.5 cm).
- You are 18 or older and in fairly good health (able to do daily activities with some help if needed).
- You have not had specific treatments like mosunetuzumab, polatuzumab vedotin, or a stem cell transplant in the recent past.
- You have a recent tumor biopsy sample available or are willing to have one taken.
- You are willing to use effective birth control if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This trial tests two new drugs, pirtobrutinib and mosunetuzumab, for people with follicular lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
This Phase 2 study tests mosunetuzumab, an antibody treatment, for people with follicular lymphoma that relapsed (came back) or progressed soon after first treatment. It may help shrink the cancer again after early relapse or lack of response to standard therapy.
This trial tests a combination of two drugs, Mosunetuzumab and Tislelizumab, for people with relapsed or refractory follicular lymphoma. The goal is to see if this combination can help when at least two prior treatments have stopped working.
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
Hear when a new Recurrent Grade 1 Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.